Last reviewed · How we verify
relenvatinib
relenvatinib is a Small molecule drug developed by RenJi Hospital. It is currently in Phase 3 development. Also known as: relenvatinib treatment.
Relenvatinib is being studied as a treatment for recurrence of hepatocellular carcinoma after liver transplantation. It is being evaluated for its efficacy and safety in this specific condition.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | relenvatinib |
|---|---|
| Also known as | relenvatinib treatment |
| Sponsor | RenJi Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- relenvatinib CI brief — competitive landscape report
- relenvatinib updates RSS · CI watch RSS
- RenJi Hospital portfolio CI
Frequently asked questions about relenvatinib
What is relenvatinib?
Who makes relenvatinib?
Is relenvatinib also known as anything else?
What development phase is relenvatinib in?
Related
- Manufacturer: RenJi Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: relenvatinib treatment
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing